FCS Contributes Late-Phase Research to Global Meeting on Gynecologic Cancer

Fort Myers, Fla., November 6, 2025 – Bradley Monk, MD, board-certified gynecologic oncologist and medical director of late-phase clinical research for Florida Cancer Specialists & Research Institute, LLC (FCS), is helping advance global understanding and treatment of gynecologic cancers at the 2025 Annual Global Meeting of the International Gynecologic Cancer Society, taking place this week in Cape Town, South Africa. As first author or co-author of six abstracts selected for presentation, Dr. Monk joins leading experts from around the world to share research, exchange best practices, and explore innovations spanning medical therapy, surgery, nursing, and global health.

“It’s an honor to share our research with an international community dedicated to improving outcomes for women with gynecologic cancers,” said FCS President & Managing Physician Lucio N. Gordan, MD. “By exchanging ideas and collaborating across disciplines, we continue to raise the standard of care throughout our local communities and worldwide.

A board-certified gynecologic oncologist, Dr. Monk leads initiatives to expand and deploy late-phase trials across the statewide FCS practice. As a principal investigator, he has been involved in numerous groundbreaking studies that are advancing treatment options and providing hope for women with gynecologic cancers. Dr. Monk noted, “Each discussion and discovery helps us move closer to more effective, compassionate care for women everywhere.”

Dr. Monk has contributed to the following abstracts selected for presentation at IGCS Conference 2025:

As co-author of an oral presentation—Pembrolizumab Plus Chemotherapy With or Without Bevacizumab in Participants With Persistent, Recurrent, or Metastatic Cervical Cancer: 5-Year Follow-Up Results

As co-author:

• As first author of an e-poster—GOG-3119/ENGOT-EN29/TROFUSE-033: A Phase 3, Randomized Study of Sacituzumab Tirumotecan Plus Pembrolizumab vs. Pembrolizumab Alone as First-Line Maintenance Therapy for Mismatch Repair-Proficient Endometrial Cancer
• Real-World Treatment Patterns of Patients With Platinum-Resistant Recurrent Ovarian Cancer Within the United States: An Analysis of Secondary Data
• Rinatabart Sesutecan Monotherapy in Patients With Advanced Endometrial Cancer: Part F of the RAINFOLTM-01 Study
• GOG-0240 Angiome
• Safety of Rucaparib Monotherapy in Advanced High-Grade Ovarian Cancer Clinical Trials

FCS provides access to advanced clinical trial options across 29 locations in Florida, bringing promising therapies closer to home for cancer patients. Over 110 new early-phase and 40 late-phase studies are launched annually. FCS has played a vital role in the development of numerous cancer drugs approved by the U.S. Food and Drug Administration (FDA).

A longstanding partnership with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, provides patients with access to a comprehensive listing of clinical trials available in the U.S. Additionally, a partnership with Paradigm Health, Inc. helps streamline and accelerate matching patients to available clinical trials.

All accepted abstracts of registered presenting authors will be published in the International Journal of Gynecological Cancer (IJGC) following the event.